Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 7—July 2008

Research

Attributable Outcomes of Endemic Clostridium difficile–associated Disease in Nonsurgical Patients

Erik R. Dubberke*Comments to Author , Anne M. Butler*, Kimberly A. Reske*, Denis Agniel*, Margaret A. Olsen*, Gina D’Angelo*, L. Clifford McDonald†, and Victoria J. Fraser*
Author affiliations: *Washington University School of Medicine, St. Louis, Missouri, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Baseline characteristics of study cohort, Clostridium difficile–associated disease (N = 18,050)*

Characteristic CDAD case-patients (n = 390), no. (%) Non–case-patients (n = 17,663), 
no. (%) p value†
Age, y
<45 58 (15) 6,847 (39) <0.001
45–65 132 (34) 5,187 (29) 0.06
>65
200 (51)
5,626 (32)
<0.001
Male sex 194 (50) 6,704 (38) <0.001
White race
257 (66)
9,860 (56)
<0.001
Modified APS
<2 77 (20) 6,687 (38) <0.001
3–4 76 (20) 4,573 (26) 0.004
5–6 82 (21) 2,970 (17) 0.028
>7
155 (40)
3,430 (19)
<0.001
Liver disease
Mild 5 (1) 204 (1) 0.77
Moderate to severe
6 (2)
209 (1)
0.47
Diabetes without chronic complications 70 (18) 2,718 (15) 0.17
Diabetes with chronic complications
15 (4)
416 (2)
0.06
Myocardial infarction 26 (7) 1466 (8) 0.25
Congestive heart failure 97 (25) 2,562 (15) <0.001
Cerebral vascular disease
16 (4)
882 (5)
0.42
Chronic obstructive pulmonary disease 90 (23) 2,564 (15) <0.001
Rheumatologic/collagen vascular disease 11 (3) 361 (2) 0.29
Peptic ulcer disease 5 (1) 279 (2) 0.64
Cancer, excluding leukemia or lymphoma 45 (12) 1,283 (7) 0.001
Leukemia or lymphoma 69 (18) 567 (3) <0.001
Metastatic solid tumor 33 (9) 936 (5) 0.01
HIV/AIDS 5 (1) 209 (1) 0.81
Paraplegia or hemiplegia 8 (2) 223 (1) 0.17

*CDAD, Clostridium difficile–associated disease; APS, Acute Physiology Score.
† Fisher exact test, χ2 test.

Main Article

TOP